Company Description
Entera Bio Ltd., a clinical stage company, focuses on developing oral peptide or protein replacement therapies for unmet medical needs.
The company leverages its N-Tab platform that is designed to simultaneously stabilize the peptide in the gastrointestinal tract and promote its absorption into the bloodstream.
It also develops EB613, an oral PTH (1-34), that has completed Phase 2 clinical trial for the treatment of post-menopausal women with low bone mineral density and high-risk osteoporosis; and has completed Phase 1 clinical trial to treat stress fractures.
In addition, the company is developing EB612, a tablet peptide replacement therapy for hypoparathyroidism.
Further, it develops oral oxyntomodulin (OXM), a dual targeted GLP1/glucagon peptide, in tablet form for the treatment of obesity and metabolic disorders; and GLP-2 peptide tablet as an injection-free alternative for patients suffering from rare malabsorption conditions, such as short bowel syndrome.
The company has research collaboration agreement with OPKO Biologics, Inc. Entera Bio Ltd. was incorporated in 2009 and is headquartered in Jerusalem, Israel.
| Country | Israel |
| Founded | 2010 |
| IPO Date | Jun 28, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 20 |
| CEO | Miranda Toledano |
Contact Details
Address: Kiryat Hadassah Minrav Building, Fifth Floor Jerusalem, 9112002 Israel | |
| Phone | 972 2 532 7151 |
| Website | enterabio.com |
Stock Details
| Ticker Symbol | ENTX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001638097 |
| CUSIP Number | M40527109 |
| ISIN Number | IL0011429839 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Miranda J. Toledano M.B.A. | Chief Executive Officer and Director |
| Dana Yaacov-Garbeli CPA | Chief Financial Officer |
| Dr. Hillel Galitzer M.B.A., Ph.D. | Chief Operating Officer |
| Dr. Gregory Burshtein Ph.D. | Chief of Research and Development |
| Dr. Rachel B. Wagman | Chief Clinical Advisor |
| Leslie Gautam | Chief Business Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 18, 2025 | 8-K | Current Report |
| Jun 6, 2025 | EFFECT | Notice of Effectiveness |
| Jun 6, 2025 | 424B3 | Prospectus |
| Jun 5, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Jun 5, 2025 | ARS | Filing |
| Jun 5, 2025 | DEF 14A | Other definitive proxy statements |
| Jun 4, 2025 | UPLOAD | Filing |
| May 30, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| May 30, 2025 | S-3 | Registration statement under Securities Act of 1933 |
| May 14, 2025 | PRE 14A | Other preliminary proxy statements |